FDA Approves New Cholesterol-Lowering Treatments

08-28-2015 Blog PostsPress Release

“The approval of Repatha is another example of a breakthrough medication with a too high price tag. With several game-changing medications in the pipeline, we need to address the underlying issue of how these prices are set from the start before they hit the market.”

PRESS STATEMENT: FDA Approves Praluent, New Cholesterol-Lowering Treatment

07-24-2015 Blog PostsPress Release

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”

The Hill: FDA approves cholesterol drug with $15,000 yearly price tag

07-24-2015 Media

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but its price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years,” John Rother, president of the National Coalition on Health Care, said in a statement.

Cancer experts call for curbs on rising drug prices

07-23-2015 Media

In recent years, increasingly specialized medications and an aging population that takes more drugs have substantially boosted the price of treatments for cancer, hepatitis C, cystic fibrosis and other diseases.

Doctors Object to High Cancer-Drug Prices

07-23-2015 Media

Amid the growing clamor, cancer medication has drawn particular ire. The average price of new cancer drugs in the U.S. increased five- to tenfold over 15 years, to more than $100,000 a year in 2012, according to the Mayo Clinic journal editorial.

$1,000-per-pill drug overtaken by pricier successor

07-11-2015 Media

The $1,000 pill for a liver-wasting viral infection that made headlines last year is no longer the favorite of patients and doctors. The new leading pill for hepatitis C is more expensive, and the number of patients seeking a cure has surged.

PwC Infographic: Costs from specialty drugs skyrocketing

06-29-2015 Media

A new PricewaterhouseCoopers report on medical cost trends highlights how specialty drugs are outpacing traditional drugs in a major way.

PRESS STATEMENT: New Kaiser Family Foundation Poll Reinforces Need for Sustainable Drug Pricing

06-16-2015 Blog PostsPress Release

John Rother, President of the National Coalition on Health Care and Chair of the Campaign for Sustainable Rx Pricing issued the following statement in response to a recent health tracking poll by the Kaiser Family Foundation that found that an overwhelming 76% of Americans blame pharmaceutical companies for the rising cost of medicines.

Skyrocketing drug prices leave cures out of reach for some patients

06-16-2015 Media

Sophisticated drugs are opening the door, scientists say, to an era of “precision medicine.” They’re also ushering in an age of astronomical prices.

ICYMI: New poll shows 75% of Americans find Rx prices are just too high.

05-21-2015 Blog PostsPress Release

May 21, 2015 Morning Consult: “New Cures, Old Problems: Poll Shows Drug Affordability Addles Americans” “The House Energy and Commerce Committee is slated to vote today on legislation that offers incentives to the pharmaceutical industry to develop new drugs and devices. But the bill does little immediately to address what a new Morning Consult poll found […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.